Redefining clinical trials: Adopting AI for speed, volume and diversity
IBM Journey to AI blog
MAY 6, 2024
In 2022, less than 10% of trial participants for FDA approval were Black, fewer than 12% were Asian, under 13% were Hispanic, and women constituted less than 50% (Exhibit 3), not reflective of the current US population. Successful clinical studies hinge on efficiently recruiting and retaining diverse participants.
144 
Let's personalize your content